• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Exploring Deal-Making Options for Your Portfolio of Assets

Thursday, June 06, 2024
Breakout Session
Business Development and Finance
29AB
As a biotech company, there are multiple ways your innovative drug technology can add value and open opportunities for new drugs. In today’s business environment, it’s essential to explore business development opportunities across a range of deal structures, offering different value propositions to fit the different strategies of potential pharma partners. You may have a single drug asset that can be the centerpiece for a partnering deal. Or you might be seeking a platform deal focused on a therapeutic area or number of targets. This session will describe the different pathways to partnership by biotech executives who have successfully executed deals across a range of structures, as well as their present-day work on BD in their current roles.
Moderator
Nisha Nanda, PhD
Group Vice President, Business Development
Eli Lilly
Speakers
Adam Rosenthal, PhD
CEO and Founder
Star Therapeutics
Bassil Dahiyat, PhD
President and Chief Executive Officer
Xencor, Inc.
James Mutamba, PhD
Chief Business Officer
Arrakis Therapeutics
Caroline Stark Beer, MBA
Chief Business Officer
Jnana Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS